| Article | Added |
|---|
| High-efficiency TALEN-based gene editing produces disease-resistant rice | -- |
| Recasting natural product research | -- |
| A work in progress | -- |
| Drug pipeline: 1Q12 | -- |
| Biotech equities heat up in 1Q12 | -- |
| Industry trial bias refuted | -- |
| Fifth time's the charm for infant respiratory distress drug | -- |
| Hypoxia-activated prodrugs forge ahead in cancer | -- |
| UK biotech's shot in the arm | -- |
| Texas legitimizes path around FDA oversight | -- |
| Blood test for Down syndrome | -- |
| 1000 genomes on Amazon's cloud | -- |
| Affymax poised to challenge Amgen | -- |
| Industry reels as Prometheus falls and Myriad faces further reviews | -- |
| JAK pot for Galapagos | -- |
| Stromedix acquisition signals growing interest in fibrosis | -- |
| Shining a light on trial data | -- |
| Biomarkers unbound | -- |
| Use of genome-wide association studies for drug repositioning | -- |
| The art of the alliance | -- |
| Addgene provides an open forum for plasmid sharing | -- |
| Tensha Therapeutics | -- |
| Positive signals from Washington | -- |
| National prescription for drug development | -- |
| Hemacord approval may foreshadow regulatory creep for HSC therapies | -- |
| India's GM clamor mounts | -- |
| Amgen swallows Micromet to BiTE into ALL market | -- |
| Biologics inch toward cholesterol-lowering market | -- |
| Corn rot. 1090 | -- |
| First HEV vaccine approved | -- |
| Biotech innovators jump on biosimilars bandwagon | -- |
| Anti-nerve growth factor drugs exonerated | -- |
| Biosimilar fees plug FDA deficit | -- |
| Oxford Nanopore announcement sets sequencing sector abuzz | -- |
| Pharma incubates without strings | -- |
| Reforming accelerated approval | -- |
| Know before you go | -- |
| Confronting the Gordian knot | -- |
| Agbiotech 2.0 | -- |
| Tiptoeing around transgenics | -- |
| Mission Therapeutics | -- |
| Existing agbiotech traits continue global march | -- |
| BASF moves GM crop research to US | -- |
| HIV neutralizing antibodies reignite interest in vaccine | -- |
| RNAi patent win | -- |
| Hedgehog hopes lifted by approval... and stung by failure | -- |
| NCATS launches | -- |
| Cystic fibrosis drug Vertex's latest triumph | -- |
| Check a patent at WIPO | -- |
| Companies in rapid pursuit of Btk immunokinase | -- |
| One patent for Europe | -- |
| Diabetes once-weekly drug | -- |
| Agnostic about agriculture | -- |
| Another nail in the biosimilar coffin? | -- |
| OpenVigil?free eyeballs on AERS pharmacovigilance data | -- |
| The blinded buyer | -- |
| Planning for the exit | -- |
| PRIDE Inspector: a tool to visualize and validate MS proteomics data | -- |
| 2011?Big biotechs gorge on debt | -- |
| Fresh from the pipeline 2011 | -- |
| UK government unveils innovation booster | -- |
| Life Technologies promises $1,000 genome | -- |
| India's innovation czar | -- |
| Toll-like receptor blocker slows beta cell death in type 1 diabetes | -- |
| Enbrel patent surfaces | -- |
| Ablynx drops lead nanobody | -- |
| Gilead's $11 billion HCV bet | -- |
| Affymetrix sued for fraud | -- |
| Amyloid disease drug approved | -- |
| Sangamo's lead zinc-finger therapy flops in diabetic neuropathy | -- |
| Why genies don't go back into bottles | -- |
| Big pharma upheavals cast shadow across biotech sector | -- |
| Approval on a knife edge | -- |
| Bringing business risk into sharp focus | -- |
| The NIH's role in accelerating translational sciences | -- |
| Building stem-cell genomics in California and beyond | -- |
| Foundation Medicine | -- |
| Drug pipeline: Q411 | -- |
| Embryonic stem cell pioneer Geron exits field, cuts losses | -- |
| Russian fund steps up investments in innovative biotechs | -- |
| Monsanto to face biopiracy charges in India | -- |
| Spinal device cancer risk | -- |
| $352 million into microRNA | -- |
| Obama urges translation speed | -- |
| Pivotal FDA/Exelixis dispute | -- |
| Safety profiles come to fore as more drugs approach MS market | -- |
| Eylea approval transforms Regeneron | -- |
| Avastin loses breast cancer indication | -- |
| What happened to personalized medicine? | -- |
| Incyte comes of age with JAK inhibitor approval | -- |
| Access to human embryonic stem cell lines | -- |
| Sarbanes-Oxley overburdens biotech companies | -- |
| Generation of the potent anti-malarial drug artemisinin in tobacco | -- |
| Relative potential of biosynthetic pathways for biofuels and bio-based products | -- |
| Re-evaluating PARP1 inhibitor in cancer | -- |
| Newsmaker: Zafgen | -- |
| Shape shifting | -- |
| Near-record drug approvals | -- |
| New startup models emerge as investor landscape shifts | -- |
| Jackson's $1.1 billion makeover | -- |
| Cold-tolerant trees win | -- |
| Industry continues dabbling with open innovation models | -- |
| GlaxoSmithKline malaria vaccine phase 3 trial heralded | -- |
| Interest groups jostle to influence PDUFA V | -- |
| Conflicts of interest go online | -- |
| Shutdown by auction | -- |
| Tilting toward secrecy | -- |
| European court bans embryonic stem cell patents | -- |
| A label we don't need | -- |
| Biotech plummets in 3Q11 | -- |
| Hepatitis C: move over interferon | -- |
| In vogue with venture | -- |
| Hemophilia market awaits next-generation therapies | -- |
| The R&D partnership universe | -- |
| China eyes Western biologics | -- |
| Bispecific biologics rush | -- |
| Academia's $1,000 genome | -- |
| Industry leaders cite barriers to sequencing in trials | -- |
| NIH tightens conflict rules | -- |
| Priority voucher flops | -- |
| European ruling raises specter of mandatory GM pollen tests on honey | -- |
| 1,000 pediatric genomes | -- |
| Hedgehog inhibitor single arm | -- |
| Larger companies dominate cancer companion diagnostic approvals | -- |
| Transatlantic PML | -- |
| America Invents Act receives cautious welcome | -- |
| Big ideas and grand challenges | -- |
| Recent patent applications in drug screening | -- |
| New fluorescent probes for super-resolution imaging | -- |
| Wanted: bioprospecting consultants | -- |
| Evergreening: a common practice to protect new drugs | -- |
| A methodological framework to enhance the clinical success of cancer immunotherapy | -- |
| Pharmacogenetics and the immunogenicity of protein therapeutics | -- |
| Drug pipeline: Q311 | -- |
| Attacks on asthma | -- |
| Headwinds into opportunity | -- |
| Gilead donates patents for generics | -- |
| South Korea's stem cell approval | -- |
| ATM cash for biotechs | -- |
| Pertuzumab to bolster Roche/Genentech's breast cancer franchise? | -- |
| Engineered T-cell therapy shows efficacy in blood cancer | -- |
| 9,000 tumors for stratified medicine | -- |
| Chinese inventors catch up | -- |
| Seattle Genetics rare cancer drug sails through accelerated approval | -- |
| HIV drugs made in tobacco | -- |
| Enlightened engineering | -- |
| Why an abbreviated FDA pathway for biosimilars is overhyped | -- |
| Clarity and claims in variation/mutation databasing | -- |
| Reply to Clarity and claims in variation/mutation databasing | -- |
| The Isis manifesto | -- |
| Shaping the future of safer innovative drugs in Europe | -- |
| Biotech on pace for record year | -- |
| Trends in biotech literature 2009?2010 | -- |
| More than insulin | -- |
| Money pot for SMEs | -- |
| China's $300 billion goal | -- |
| 13,000-biomarker deal | -- |
| Patent reform on the brink | -- |
| Drugmakers use real-world patient data to calibrate product development | -- |
| BIO marches to Congress with growth package in hand | -- |
| Myriad decision reassures biotechs but diagnostics still murky | -- |
| GM grass eludes outmoded USDA oversight | -- |
| New models emerge for commercializing university assets | -- |
| Outbreak genomics | -- |
| Reply to: IMI moves forward | -- |
| Commercializing a disruptive technology | -- |
| IMI moves forward | -- |
| Newsmaker: Lycera | -- |
| Drug pipeline: Q211 | -- |
| Move over ZFNs | -- |
| Cisgenic crop exemption | -- |
| EU tolerates GM | -- |
| Supreme Court ruling prompts universities to tighten employee contracts | -- |
| FDA panel votes to pull Avastin in breast cancer, again | -- |
| Novel schemes skirt NICE barrier | -- |
| FDA approves first cell therapy for wrinkle-free visage | -- |
| FDA inspections online | -- |
| Australian biotechs rejoice | -- |
| Swiss food giant enters diagnostics | -- |
| US court bolsters biotech patent protection | -- |
| Pushing the envelope | -- |
| E. coli crisis opens door for Alexion drug trial | -- |
| TNF-? blockers and tumors | -- |
| Scant evidence supports EPA's pyramided Bt corn refuge size of 5% | -- |
| Industry access to the literature | -- |
| Sequencing technology does not eliminate biological variability | -- |
| Anti-galactose-?-1,3-galactose IgE from allergic patients does not bind ?-galactosylated glycans on intact therapeutic antibody Fc domains | -- |
| Psoriasis: from bed to bench and back | -- |
| Granting you success | -- |
| Teva hits bull's eye with Cephalon | -- |
| Amgen's Brazilian buying spree | -- |
| Biologic Indian detour adds value | -- |
| French bioethics turmoil | -- |
| Life sciences firms cheer unlocking of National Health Service | -- |
| Gates eyes biotechs as for-profit investments | -- |
| Alkermes, Elan in $960 million merger | -- |
| Avastin as good as Lucentis | -- |
| Optimer resurrects C. difficile antibiotic to win approval | -- |
| New self-reporting for GM crops | -- |
| Members need only apply | -- |
| New Merck and Vertex drugs raise standard of care in hepatitis C | -- |
| Biotechs follow big pharma lead back into academia | -- |
| In this issue | -- |
| Recurrent copy number variations in human induced pluripotent stem cells | -- |
| Is silence still golden? Mapping the RNAi patent landscape | -- |
| Quantitative analysis demonstrates most transcription factors require only simple models of specificity | -- |
| Jury remains out on simple models of transcription factor specificity | -- |
| US attitudes toward human embryonic stem cell research | -- |
| Raising hairs | -- |
| What mergers can do for you | -- |
| Intranasal delivery to the brain | -- |
| Spat over IMI funding and intellectual property | -- |
| Monsanto dips into algae | -- |
| Bayer's GM rice defeat | -- |
| Blue skies ready for investors | -- |
| Chinese vaccine developers gain WHO imprimatur | -- |
| GM bananas | -- |
| Stem cell funding resumes | -- |
| Debate re-ignites on contribution of public research to drug development | -- |
| Supreme setback for pharma | -- |
| First cystic fibrosis drug advances towards approval | -- |
| Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis | -- |
| The sequence is dead: long live the genome | -- |
| Mandating race: how the USPTO is forcing race into biotech patents | -- |
| Interaction databases on the same page | -- |
| PathSeq: software to identify or discover microbes by deep sequencing of human tissue | -- |
| Reforming direct-to-consumer advertising | -- |
| Peering inside Alzheimer's brains | -- |
| Safe and sound | -- |
| Overhauling the reimbursement system for molecular diagnostics | -- |
| Around the world in a month | -- |
| Q1 strong out of the gates | -- |
| Drug pipeline: Q111 | -- |
| OncoTrack tests drugs in virtual people | -- |
| Sequencing firms eye pathology labs as next big market opportunity | -- |
| Flawed arithmetic on drug development costs | -- |
| $1.3 billion to translate | -- |
| Pharma wins vaccine case | -- |
| Chinese biotechs wrestle with transparency, cultural hurdles | -- |
| PARP inhibitors stumble in breast cancer | -- |
| Melanoma antibody approved | -- |
| Human iPSC and ESC translation potential debated | -- |
| Inadequately met needs | -- |
| Karyotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells | -- |
| Intellectual property rights in publicly funded biobanks: much ado about nothing? | -- |
| Recent patent applications in gene expression | -- |
| Acceptable changes in quality attributes of glycosylated biopharmaceuticals | -- |
| Karotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells | -- |
| EU legitimizes GM crop exclusion zones | -- |
| GM crop cultivation surges, but novel traits languish | -- |
| Mixed messages from Washington | -- |
| For the records | -- |
| Open access consortium | -- |
| Researchers cut loose as Pfizer and Merck shutter European sites | -- |
| Architects meet stem cells | -- |
| p38 kinase inhibitor approved for idiopathic pulmonary fibrosis | -- |
| Irish bioprocessing school | -- |
| Pharma interest surges in antibody drug conjugates | -- |
| Benlysta makes history | -- |
| Amylase corn sparks worries | -- |
| Amgen spikes interest in live virus vaccines for hard-to-treat cancers | -- |
| Large drugs outdo small | -- |
| Sharing secrets | -- |
| Genzyme-Sanofi buyout is second largest biotech deal ever | -- |
| Elias Zerhouni | -- |
| Edison Liu | -- |
| Anthony Coyle | -- |
| Paul Keckley | -- |
| Merv Turner | -- |
| Video games played with live organisms | -- |
| Gary Pisano | -- |
| Stelios Papadopoulos | -- |
| Alzheimer's genetic map | -- |
| Industry exhales as USDA okays glyphosate-resistant alfalfa | -- |
| Yardsticks for R&D | -- |
| DuPont swallows Danisco | -- |
| Biosimilars encircle Rituxan, US debates innovator exclusivity | -- |
| NCI revamps trials | -- |
| Dreamboat sinks prospects for fast approval of inhaled insulin | -- |
| Courts back Prometheus IP | -- |
| Accelerated approvals examined | -- |
| Realigning interests | -- |
| Fate of novel painkiller mAbs hangs in balance | -- |
| Novel agents combined get own guidance | -- |
| The 2010 Eurobarometer on the life sciences | -- |
| Balancing open source stem cell science with commercialization | -- |
| 2010?bumper year for big biotech | -- |
| Natural-born eaters | -- |
| Something new under the skin | -- |
| Streamlining your business for success | -- |
| First public-private vaccine | -- |
| Mobile vaccine factories | -- |
| Drug pipeline: Q410 | -- |
| Imperial's £140 million boost | -- |
| Cephalon splashes out on mesenchymal stem cells | -- |
| Fabry drug march-in denied | -- |
| Trade secrets in balance as agencies issue new transparency rules | -- |
| Synthetic biology go ahead | -- |
| RNAi momentum fizzles as pharma shifts priorities | -- |
| ReNeuron and StemCells get green light for neural stem cell trials | -- |
| China calling | -- |
| Testing times for gene test regulators | -- |
| Industry gives cautious welcome to NIH translational center | -- |
| Is transgenic maize what Mexico really needs? | -- |
| Breaking the mold | -- |
| Battling infringement | -- |
| Essential information for synthetic DNA sequences | -- |
| Reply to Essential information for synthetic DNA sequences | -- |
| EU mAb biosimilars path | -- |
| Vatican panel backs GMOs | -- |
| Newsmaker: Biocentury Transgene | -- |
| Can cancer clinical trials be fixed? | -- |
| Temporary ban on clones | -- |
| Filipinos back GM eggplant | -- |
| Science snipes at Oxitec transgenic-mosquito trial | -- |
| European R&D buoyant | -- |
| Boehringer splashes out on bispecific antibody platforms | -- |
| Biogen Idec restructures, sharpens neurology focus | -- |
| Roche cuts Genentech jobs | -- |
| Company Bridge Awards | -- |
| Similarity trials | -- |
| Pfizer reaches out to academia?again | -- |
| Amgen's bone-metastasis win | -- |
| Wrong fixes for gene patents | -- |
| Reply to Wrong fixes for gene patents | -- |
| Stem cell clinics in the news | -- |
| Tracking and assessing the rise of state-funded stem cell research | -- |
| Towards a knowledge-based Human Protein Atlas | -- |
| Good ideas across borders | -- |
| Airlines ahead on algae | -- |
| Crossing the line | -- |
| New twists on proteasome inhibitors | -- |
| Around the block | -- |
| BARDA funds vaccine makers aiming to phase out eggs | -- |
| Vaccine makers' immunity questioned in court | -- |
| Singapore injects $12.5 billion | -- |
| Ethanol blend hike to jump start cellulosic investment | -- |
| Will J&J turbocharge Crucell's vaccine portfolio? | -- |
| Amylin's diabetes shock | -- |
| Synthetic DNA firms embrace hazardous agents guidance but remain wary of automated 'best-match' | -- |
| DNA not patentable | -- |
| USPTO's do-good vouchers | -- |
| Vive la différence? | -- |
| Making the leap into entrepreneurship | -- |
| Grant management skills are critical for young scientists | -- |
| Chinese hamster ovary cells can produce galactose-?-1,3-galactose antigens on proteins | -- |
| A policy approach to the development of molecular diagnostic tests | -- |
| What is the value of oncology medicines? | -- |
| Sanofi/Genzyme hostile | -- |
| Adverse-events fraud trial | -- |
| Newsmaker: Anaphore | -- |
| Biotech rallies in Q3 | -- |
| When patients march in | -- |
| Joint inspections still cool | -- |
| Stimulus trickle | -- |
| CIRM spurs translation | -- |
| Irish bait | -- |
| Transgenic salmon inches toward finish line | -- |
| Novartis eyes oral MS drug as potential blockbuster | -- |
| Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall | -- |
| Pharmacogenomics row | -- |
| Shire's replacement enzymes validate gene activation | -- |
| Conflicts and collaborations | -- |
| At the heart of genetic testing | -- |
| Why you need a lawyer | -- |
| Safe and effective synthetic biology | -- |
| Hungary eyes biotech jobs | -- |
| Monsanto relaxes restrictions on sharing seeds for research | -- |
| Newsmaker: Constellation Pharmaceuticals | -- |
| Drug pipeline: Q310 | -- |
| Turning the tide in lung cancer | -- |
| Life swallows Ion Torrent | -- |
| Anti-anemics price hike | -- |
| Genzyme resumes shipping as Sanofi-aventis hovers | -- |
| Cancer research fund launches biologics pilot plant | -- |
| Wellcome partners with India | -- |
| China's $2.4 billion splurge | -- |
| US courts throw ES cell research into disarray | -- |
| Drug user fees top $1 million | -- |
| Sugar beets still in the game | -- |
| Roche backs Aileron's stapled peptides | -- |
| Teetering on the brink | -- |
| Geron trial resumes, but standards for stem cell trials remain elusive | -- |
| Global health or global wealth? | -- |
| Oncology's energetic pipeline | -- |
| Disclosing discoveries | -- |
| The Cartagena Protocol and genetically modified mosquitoes | -- |
| The FEBS Letters/BioCreative II.5 experiment: making biological information accessible | -- |
| Biofortified sorghum in Africa: using problem formulation to inform risk assessment | -- |
| Towards patient-based cancer therapeutics | -- |
| Brazil bans Bayer | -- |
| India's Cipla sets sights on Avastin, Herceptin and Enbrel | -- |
| Stem cell clinic patrol | -- |
| EC woos SMEs | -- |
| Cochrane meta-analysis on alpha-1 antitrypsin prompts furor | -- |
| Trends in biotech literature 2009 | -- |
| Avastin's commercial march suffers setback | -- |
| Sanofi-aventis snaps up microRNA maker | -- |
| Pfizer explores rare disease path | -- |
| Provenge twists again | -- |
| Lilly snaps up Alnara | -- |
| TTO patent swap | -- |
| The identity problem | -- |
| Waking up and smelling the coffee | -- |
| Reply to Waking up and smelling the coffee | -- |
| Genetic stability in two commercialized transgenic lines (MON810) | -- |
| Distances needed to limit cross-fertilization between GM and conventional maize in Europe | -- |
| Case study: India's billion dollar biotech | -- |
| EU states free to ban GM crops | -- |
| Food firms test fry Pioneer's trans fat?free soybean oil | -- |
| GM alfalfa?who wins? | -- |
| Biofuel 'Made in China' | -- |
| 2Q10'spreading the wealth | -- |
| Drugmakers dance with autism | -- |
| At ground level | -- |
| Industry makes strides in melanoma | -- |
| Firms combine experimental cancer drugs to speed development | -- |
| Supremes rule on Bilski | -- |
| FDA transparency rules could hit small companies hardest | -- |
| Lawsuits rock Jackson | -- |
| Anti-CD20 patent battle ends | -- |
| Wrong numbers? | -- |
| MAQC-II: analyze that! | -- |
| Sunshine on conflicts | -- |
| Ask your doctor | -- |
| PeptideClassifier for protein inference and targeted quantitative proteomics | -- |
| Minimum information about a protein affinity reagent (MIAPAR) | -- |
| Merck ditches biogeneric | -- |
| Investors fight Charles River/WuXi merger | -- |
| Genzyme partners TJAB | -- |
| China's heparin billionaires | -- |
| Microcap public biotechs access new pool of VC funding | -- |
| Italian GM rebels | -- |
| Newsmaker: Agios Pharmaceuticals | -- |
| Drug pipeline: Q210 | -- |
| Consortia and commodities | -- |
| Pharma embraces open source models | -- |
| New eyes on old drugs | -- |
| Genetic testing clamp down | -- |
| New tech transfer models gain traction with deal flow | -- |
| French IPO spate | -- |
| Industrial biotech to boom? | -- |
| Sequencing firms vie for diagnostics market, tiptoe round patents | -- |
| Why drought tolerance is not the new Bt | -- |
| Health impact in China of folate-biofortified rice | -- |
| Obama appoints bioethics panel to offer practical advice | -- |
| GSK's RNA splash | -- |
| Germany caps drug prices | -- |
| Biotech breeding goes bovine | -- |
| Up for grabs | -- |
| Beyond venture capital | -- |
| 1 out of 27?European politicians score poorly in agbiotech | -- |
| Split approvals and hot potatoes | -- |
| Landmark approval for Dendreon's cancer vaccine | -- |
| Firms chase diabetic inflammation with anti-IL-1? antibodies | -- |
| African GM safety drill | -- |
| Burgeoning stem cell product market lures major suppliers | -- |
| GMP cell lines to order | -- |
| Open-access fermenter | -- |
| Glyphosate resistance threatens Roundup hegemony | -- |
| SBIR grants wax | -- |
| Relief over stem cell lines | -- |
| An empiric victory | -- |
| Above water in Q1 | -- |
| How green biotech turned white and blue | -- |
| Drug marketing and the new media | -- |
| Avoiding capital punishment | -- |
| Natural variation in crop composition and the impact of transgenesis | -- |
| GM crops and gender issues | -- |
| BIO's track record on emerging companies | -- |
| South-South entrepreneurial collaboration in health biotech | -- |
| Open biotechnology: licenses needed | -- |
| Recent patent applications in fluorescent imaging | -- |
| Sitting up and taking notice | -- |
| Biomarker-led adaptive trial blazes a trail in breast cancer | -- |
| Biotechs adjust to new landscape as US healthcare reform takes off | -- |
| Genentech, UCSF discovery pact | -- |
| Abbott outbids Biogen for Facet's multiple sclerosis antibody | -- |
| FDA crackdown on Genzyme | -- |
| Ariad's NF-?B blow | -- |
| Orphan drug workshops | -- |
| Texas splurges on cancer | -- |
| Chinese green light for GM rice and maize prompts outcry | -- |
| Public companies get creative in raising finance | -- |
| ReNeuron first in stroke | -- |
| Erythropoietins locked into risk management program | -- |
| Stem cells to order | -- |
| EPA releases land-use rule for biofuels to mixed reception | -- |
| Shell's billions to convert Brazilian biomass into fuel | -- |
| 2nd-generation GM traits progress | -- |
| Fresh from the biologic pipeline?2009 | -- |
| Biotech in a blink | -- |
| Selling out | -- |
| Making the most of GM potatoes | -- |
| What health reform means for innovation | -- |
| Safety signal dampens reception for mipomersen antisense | -- |
| Bt brinjal splits Indian cabinet | -- |
| Orphans on the rise | -- |
| Pharma's Asian syndicate | -- |
| Roche plans for more convenient-to-use Herceptin and Rituxan | -- |
